首页> 外文OA文献 >Strain-dependent responses to mineral hydrocarbons in female Fischer-344 and Sprague-Dawley rats
【2h】

Strain-dependent responses to mineral hydrocarbons in female Fischer-344 and Sprague-Dawley rats

机译:雌性Fischer-344和Sprague-Dawley大鼠对矿物质碳氢化合物的应变依赖性反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Mineral hydrocarbons (MHC) produce hepatic microgranulomas and granulomas following repeated administration to female Fischer-344 (F-344) rats. Female Sprague-Dawley (S-D) rats are less sensitive to these MHC-induced hepatic effects. Comparative studies were conducted to characterize the pharmacokinetics and disposition of a representative C26 MHC, [1-14C]1-eicosanylcyclohexane ([14C]EICO), in these two rat strains. Following a single oral dose of MHC, F-344 rats had a higher blood Cmax of [14C]EICO, a longer time to Cmax, and a greater blood AUC compared to S-D rats. Fecal excretion was the major route of elimination of parent [ 14C]EICO for both rat strains. Both rat strains eliminated 11% of the dose in the urine by 96 h. However, S-D rats eliminated the majority of [14C]EICO-metabolites in the urine by 16 h, while F-344 rats excreted [14C] equivalents in a time-dependent manner. At 96 h, 3% of the radioactive dose was recovered in livers of F-344 rats, but only 0.1% in S-D rats. Parent [14C]EICO was determined to be retained in livers of F-344 rats. Only metabolites of [14C]EICO were present in urine, the two major being 12-cyclohexyldodecanoic acid and 10-cyclohexyldecanoic acid. Inhibition of hepatic P450 activity using ABT prior to MHC administration resulted in a significant increase in [14C]EICO retention in livers of F-344 rats at 96 h. Pretreatment with clofibrate, a CYP4A inducer, decreased the amount of [14C]EICO retained in livers of F-344 rats at 96 h. Dietary exposure from MHC for 2 weeks resulted in an increased amount of MHC retained in livers of F-344 rats, whereas little was retained in treated S-D rats. The majority of MHC was retained in hepatocytes, whereas little was detected in Kupffer cells (KC). This was evidenced following transmission electron microscopy analysis of liver sections of F-344 rats. Multiple MHC droplets were observed in hepatocytes, while few droplets were detected in KC. Results from these studies suggest that inherent strain-differences in systemic exposure, rates of elimination, and hepatic retention of MHC exist following MHC exposure. The CYP4 enzyme family plays a role in the metabolism, clearance, and retention of [14C]EICO, while the phagocytic activity of KC is less significant after a single oral dose of MHC. In addition, repeated exposure of MHC alters the morphology of hepatocytes of F-344 rats but not S-D rats. These differences just described suggest that F-344 rats are inherently predisposed to the observed MHC-induced hepatic effects. (Abstract shortened by UMI.)
机译:反复向雌性Fischer-344(F-344)大鼠给药后,矿物质碳氢化合物(MHC)会产生肝微肉芽肿和肉芽肿。雌性Sprague-Dawley(S-D)大鼠对这些MHC诱导的肝效应较不敏感。进行了比较研究,以表征这两种大鼠品系中代表性的C26 MHC [1-14C] 1-二十碳烷基环己烷([14C] EICO)的药代动力学和分布。与S-D大鼠相比,单次口服MHC后,F-344大鼠的[14C] EICO血液Cmax更高,达到Cmax的时间更长,血液AUC更大。粪便排泄是消除两种大鼠品系亲本[14C] EICO的主要途径。两种大鼠品系在96小时内消除了尿液中11%的剂量。然而,S-D大鼠在16小时内消除了尿液中的大多数[14C] EICO代谢物,而F-344大鼠则以时间依赖性方式排泄了[14C]当量。在96小时时,在F-344大鼠的肝脏中回收了3%的放射性剂量,但在S-D大鼠中仅回收了0.1%。确定了亲本[14C] EICO被保留在F-344大鼠的肝脏中。尿液中仅存在[14C] EICO的代谢物,两个主要代谢物是12-环己基十二烷酸和10-环己基癸酸。在施用MHC之前,使用ABT抑制肝P450活性导致F-344大鼠肝脏在96小时时[14C] EICO保留显着增加。氯贝贝特(一种CYP4A诱导剂)预处理可降低F-344大鼠肝脏在96小时内保留的[14C] EICO量。饮食中MHC暴露2周导致F-344大鼠肝脏中保留的MHC数量增加,而经治疗的S-D大鼠中保留的MHC很少。 MHC的大部分保留在肝细胞中,而在Kupffer细胞(KC)中几乎没有检测到。 F-344大鼠肝脏切片的透射电镜分析证实了这一点。在肝细胞中观察到多个MHC小滴,而在KC中检测到很少的小滴。这些研究的结果表明,MHC暴露后,MHC的全身暴露,清除率和肝保留存在固有的应变差异。 CYP4酶家族在[14C] EICO的代谢,清除和保留中起着作用,而单次口服MHC后KC的吞噬活性不太显着。此外,反复接触MHC会改变F-344大鼠而非S-D大鼠肝细胞的形态。刚刚描述的这些差异表明F-344大鼠天生就倾向于观察到的MHC诱导的肝效应。 (摘要由UMI缩短。)

著录项

  • 作者

    Halladay Jason;

  • 作者单位
  • 年度 2002
  • 总页数
  • 原文格式 PDF
  • 正文语种 en_US
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号